Precision BioSciences, Inc. (DTIL)
| Market Cap | 113.16M |
| Revenue (ttm) | 102.50M |
| Net Income (ttm) | -40.08M |
| Shares Out | 62.18M |
| EPS (ttm) | -0.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 333,836 |
| Open | 1.82 |
| Previous Close | 1.89 |
| Day's Range | 1.78 - 1.95 |
| 52-Week Range | 1.49 - 14.38 |
| Beta | 1.61 |
| Analysts | Buy |
| Price Target | 12.11 (+565.4%) |
| Earnings Date | May 9, 2022 |
About DTIL
Precision BioSciences, Inc., a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial ...
Financial Performance
In 2021, DTIL's revenue was $115.53 million, an increase of 375.72% compared to the previous year's $24.29 million. Losses were -$30.60 million, -71.93% less than in 2020.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for DTIL stock is "Buy." The 12-month stock price forecast is 12.11, which is an increase of 565.38% from the latest price.
News
Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Soc...
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ASGCT22--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editi...
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, toda...
Precision BioSciences (DTIL) Reports Q1 Loss, Misses Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 20.69% and 33.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editin...
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cel...
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editin...
Precision BioSciences to Report First Quarter 2022 Financial Results on May 9, 2022
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editin...
Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 20.83% and 23.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editin...
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2021 Results on March 15, 2022
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editin...
What to Expect From Precision BioSciences (DTIL) Q4 Earnings
On Precision BioSciences' (DTIL) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline.
Precision BioSciences (DTIL) Stock Sinks As Market Gains: What You Should Know
Precision BioSciences (DTIL) closed the most recent trading day at $4.82, moving -0.62% from the previous trading session.
Precision BioSciences (DTIL) Gains But Lags Market: What You Should Know
In the latest trading session, Precision BioSciences (DTIL) closed at $4.86, marking a +0.83% move from the previous day.
Precision BioSciences to Present at the 40th Annual J.P. Morgan Health Care Conference
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies wit...
Precision BioSciences Completes Spin-Out of Elo Life Systems
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies wit...
Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ASH21--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T an...
Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data a...
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ASH21--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T an...
Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the ...
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T an...
Wall Street Analysts See a 98% Upside in Precision BioSciences (DTIL): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 98% in Precision BioSciences (DTIL). While the effectiveness of this highly sought-after metric is questionable, ...
Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 68.33% and 181.35%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #earnings--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T...
Precision BioSciences Earnings Preview
Precision BioSciences (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Wednesday, 2021-11-10. Here's what investors need to know before the announcement.
Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at Th...
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #SITC21--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T a...
Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D.
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vi...
Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Im...
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ASH21--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T an...
Precision BioSciences to Report Third Quarter 2021 Financial Results on November 10, 2021 and Participate in the Stif...
DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vi...